retatrutide approval 2025 fda The FDA has issued warning letters to multiple companies marketing compounded Retatrutide Retatrutide FDA Approval Timeline 2026-2028:

Patients with uncontrolled or partially controlled hyperthyroidism face compounded cardiovascular strain when adding GLP-1 therapy, making pre-treatment medical evaluation essential

SHBG (Sex Hormone-Binding Globulin): The protein that binds to testosterone, making it inactive

Semaglutide and tirzepatide also make people feel fuller and eat less, curbing the appetite and slowing stomach emptying

As Novo Nordisk and Eli Lilly $LLY struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, healthcare companies are introducing supply trackers to help patients navigate ongoing shortages.